passage bio inc stock

The Company is focused on developing transformative therapies for. At the very opening of the session the stock price was 226 and reached a high price of 264.

Passage Bio Inc Investors And News Stock Information

Our focus is on producing medicines that will transform the lives of patients and their families.

. PHILADELPHIA June 09 2022 GLOBE NEWSWIRE - Passage Bio Inc. 24 2022 GLOBE NEWSWIRE -- Passage Bio Inc. PASG a clinical-stage genetic medicines company focused on.

PASG stock news and headlines to help you in your trading and investing decisions. ET by Ciara Linnane. PASG is priced at 259 after the most recent trading session.

Friendly Platforms Trading today. PASG stock price quote stock graph news analysis. On average they anticipate Passage Bios share price to.

Passage Bio Inc. Price and volume over 1Y period View as data table Passage Bio Inc. PHILADELPHIA June 09 2022 GLOBE NEWSWIRE -- Passage Bio Inc.

Their forecasts range from 600 to 3400. Is a clinical stage genetic medicines company. Through our partnership with the University of Pennsylvanias Gene Therapy Program GTP.

It focuses on developing transformative therapies for rare monogenic central nervous system disorders with. Get Passage Bio Inc PASGNASDAQ real-time stock quotes news price and financial information from CNBC. What are analysts forecasts for Passage Bio stock.

Passage Bio has a 1 year low of 157 and a 1 year high of 1614. Chart represents Passage Bio Inc. Operates as a genetic medicines company.

Company facts information and financial ratios from MarketWatch. 6 analysts have issued 12 month price objectives for Passage Bios shares. Genetic medicines company Passage Bio to offer 74 million shares in IPO priced at 16 to 18 each.

18 2020 at 653 am. Company profile page for Passage Bio Inc including stock price company news press releases executives board members and contact information. Please note that any opinions estimates or.

PASG 222 017 829. PASG real-time share value investment rating and financial market information from Capital. The 13 analysts offering price forecasts for Passage Bio have a median target of 2462 with a high estimate of 4500 and a low estimate.

PASG announced Wednesday that the US. Price and volume The chart has 1. Passage Bio Inc NASDAQ Updated Jun 3 2022 1144 PM.

The stock has a market capitalization of 14066 million a PE ratio of -074 and a beta of 185. Combination chart with 2 data series. Real time Passage Bio Inc.

Get the latest Passage Bio Inc. PASG a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders today announced that Simona King chief financial officer of Passage Bio will participate in a fireside chat at the upcoming Goldman Sachs 43rd. Food and Drug Administration FDA has cleared its Investigational.

Is followed by the analysts listed above. Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3 2022. Get Passage Bio Inc.

2 days agoRTTNews - Genetic medicines company Passage Bio Inc. Primary metrics and data points about Passage Bio Inc.

Passage Bio Stock Worth Keeping An Eye On Nasdaq Pasg Seeking Alpha